Cholinergic deficiency and frontal dysfunction in Parkinson's disease.
Identifieur interne : 001818 ( PubMed/Corpus ); précédent : 001817; suivant : 001819Cholinergic deficiency and frontal dysfunction in Parkinson's disease.
Auteurs : B. Dubois ; B. Pilon ; F. Lhermitte ; Y. AgidSource :
- Annals of neurology [ 0364-5134 ] ; 1990.
English descriptors
- KwdEn :
- Afferent Pathways (drug effects), Cholinergic Fibers (drug effects), Cognition Disorders (etiology), Cognition Disorders (physiopathology), Frontal Lobe (drug effects), Frontal Lobe (physiopathology), Humans, Levodopa (therapeutic use), Parasympatholytics (adverse effects), Parasympatholytics (therapeutic use), Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Psychological Tests.
- MESH :
- chemical , adverse effects : Parasympatholytics.
- chemical , therapeutic use : Levodopa, Parasympatholytics.
- complications : Parkinson Disease.
- drug effects : Afferent Pathways, Cholinergic Fibers, Frontal Lobe.
- drug therapy : Parkinson Disease.
- etiology : Cognition Disorders.
- physiopathology : Cognition Disorders, Frontal Lobe, Parkinson Disease.
- Humans, Psychological Tests.
Abstract
To investigate the influence of central cholinergic deficit on cognitive function in Parkinson's disease (PD), we compared the neuropsychological performance of a group of 20 patients who were treated with anticholinergic drugs (mean daily dose, 10.2 mg) with that of a group of 20 patients who received no anticholinergics. The two groups were matched for all the variables of parkinsonism and levodopa therapy. At the dose used, there was no significant difference between the two groups of patients for intellectual, visuospatial, instrumental, and memory function. In contrast, in the group that received anticholinergics severe impairment was observed on tests believed to assess frontal lobe function. These results suggest that the lesion of the ascending cholinergic neurons, which has been demonstrated post mortem in PD, may play a role in the subcorticofrontal behavioral impairment of this disease.
DOI: 10.1002/ana.410280202
PubMed: 2221841
Links to Exploration step
pubmed:2221841Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cholinergic deficiency and frontal dysfunction in Parkinson's disease.</title><author><name sortKey="Dubois, B" sort="Dubois, B" uniqKey="Dubois B" first="B" last="Dubois">B. Dubois</name><affiliation><nlm:affiliation>Inserm U 289 et Clinique de Neurologie et Neuropsychologie, Hôpital de la Salpêtrière, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Pilon, B" sort="Pilon, B" uniqKey="Pilon B" first="B" last="Pilon">B. Pilon</name></author><author><name sortKey="Lhermitte, F" sort="Lhermitte, F" uniqKey="Lhermitte F" first="F" last="Lhermitte">F. Lhermitte</name></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Y. Agid</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1990">1990</date><idno type="RBID">pubmed:2221841</idno><idno type="pmid">2221841</idno><idno type="doi">10.1002/ana.410280202</idno><idno type="wicri:Area/PubMed/Corpus">001818</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001818</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cholinergic deficiency and frontal dysfunction in Parkinson's disease.</title><author><name sortKey="Dubois, B" sort="Dubois, B" uniqKey="Dubois B" first="B" last="Dubois">B. Dubois</name><affiliation><nlm:affiliation>Inserm U 289 et Clinique de Neurologie et Neuropsychologie, Hôpital de la Salpêtrière, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Pilon, B" sort="Pilon, B" uniqKey="Pilon B" first="B" last="Pilon">B. Pilon</name></author><author><name sortKey="Lhermitte, F" sort="Lhermitte, F" uniqKey="Lhermitte F" first="F" last="Lhermitte">F. Lhermitte</name></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Y. Agid</name></author></analytic><series><title level="j">Annals of neurology</title><idno type="ISSN">0364-5134</idno><imprint><date when="1990" type="published">1990</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Afferent Pathways (drug effects)</term><term>Cholinergic Fibers (drug effects)</term><term>Cognition Disorders (etiology)</term><term>Cognition Disorders (physiopathology)</term><term>Frontal Lobe (drug effects)</term><term>Frontal Lobe (physiopathology)</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Parasympatholytics (adverse effects)</term><term>Parasympatholytics (therapeutic use)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Psychological Tests</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Parasympatholytics</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Levodopa</term><term>Parasympatholytics</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Afferent Pathways</term><term>Cholinergic Fibers</term><term>Frontal Lobe</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cognition Disorders</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Cognition Disorders</term><term>Frontal Lobe</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Psychological Tests</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To investigate the influence of central cholinergic deficit on cognitive function in Parkinson's disease (PD), we compared the neuropsychological performance of a group of 20 patients who were treated with anticholinergic drugs (mean daily dose, 10.2 mg) with that of a group of 20 patients who received no anticholinergics. The two groups were matched for all the variables of parkinsonism and levodopa therapy. At the dose used, there was no significant difference between the two groups of patients for intellectual, visuospatial, instrumental, and memory function. In contrast, in the group that received anticholinergics severe impairment was observed on tests believed to assess frontal lobe function. These results suggest that the lesion of the ascending cholinergic neurons, which has been demonstrated post mortem in PD, may play a role in the subcorticofrontal behavioral impairment of this disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2221841</PMID><DateCreated><Year>1990</Year><Month>11</Month><Day>16</Day></DateCreated><DateCompleted><Year>1990</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0364-5134</ISSN><JournalIssue CitedMedium="Print"><Volume>28</Volume><Issue>2</Issue><PubDate><Year>1990</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann. Neurol.</ISOAbbreviation></Journal><ArticleTitle>Cholinergic deficiency and frontal dysfunction in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>117-21</MedlinePgn></Pagination><Abstract><AbstractText>To investigate the influence of central cholinergic deficit on cognitive function in Parkinson's disease (PD), we compared the neuropsychological performance of a group of 20 patients who were treated with anticholinergic drugs (mean daily dose, 10.2 mg) with that of a group of 20 patients who received no anticholinergics. The two groups were matched for all the variables of parkinsonism and levodopa therapy. At the dose used, there was no significant difference between the two groups of patients for intellectual, visuospatial, instrumental, and memory function. In contrast, in the group that received anticholinergics severe impairment was observed on tests believed to assess frontal lobe function. These results suggest that the lesion of the ascending cholinergic neurons, which has been demonstrated post mortem in PD, may play a role in the subcorticofrontal behavioral impairment of this disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Inserm U 289 et Clinique de Neurologie et Neuropsychologie, Hôpital de la Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pilon</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Lhermitte</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Agid</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010276">Parasympatholytics</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000344" MajorTopicYN="N">Afferent Pathways</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002799" MajorTopicYN="N">Cholinergic Fibers</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010276" MajorTopicYN="N">Parasympatholytics</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011581" MajorTopicYN="N">Psychological Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2221841</ArticleId><ArticleId IdType="doi">10.1002/ana.410280202</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001818 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001818 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:2221841
|texte= Cholinergic deficiency and frontal dysfunction in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:2221841" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |